Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2024
0mins
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks declined mid-trading, with the Dow Jones falling 150 points, while real estate shares rose by 1.5% and energy shares dropped by 2%.
Company Earnings Highlights: Goldman Sachs reported better-than-expected revenue for Q3, while Wolfspeed and MeiraGTx saw significant stock increases due to funding announcements and positive study results, respectively; however, Seelos Therapeutics faced a 52% drop after a delisting notice.
Analyst Views on MGTX
Wall Street analysts forecast MGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGTX is 23.00 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.690
Low
15.00
Averages
23.00
High
30.00
Current: 7.690
Low
15.00
Averages
23.00
High
30.00
About MGTX
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
